BOSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025 at 8:40 a.m. ET. The fireside chat will be webcasted and avai ...

Shares of Rhythm Pharmaceuticals, Inc. (RYTM) have gained 0.3% over the past four weeks to close the last trading session at $56.52, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $71.42 indicates a potential upside of 26.4%.The mean estimate comprises 12 short-term price targets with a standard deviation of $6.87. While the lowest estimate of $60 indicates a 6.2% increase from ...

Rhythm Pharmaceuticals, Inc. (RYTM) shares soared 5.5% in the last trading session to close at $57.52. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.7% loss over the past four weeks.Earlier this month, the company announced robust preliminary results for the fourth quarter and full-year 2024. Preliminary net revenues from worldwide sales of Imcivree (setmelanotide) were around $42 million for the fourth quarter of 2024 and ap ...

Rhythm Pharmaceuticals January 2025 © Rhythm® Pharmaceuticals, Inc. All rights reserved. Exhibit 99.2 Forward Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, ar ncertainties, including without limitation statements regarding the potential, safety, efficacy, and regulatory and clinical progress of setmel (formerly LB54640), and RM718, including the anticipated timing for initiation of clinical trials ...

-- Preliminary unaudited net revenues from global sales of IMCIVREE® (setmelanotide) of approximately $42 million for the fourth quarter of 2024 and approximately $130 million for the full year of 2024 -- -- On track to report topline data from global Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity in the first half of 2025 -- -- Completed enrollment in supplemental Japanese cohort of Phase 3 trial of setmelanotide in acquired hypothalamic obesity -- -- Completed enrollment in two ...

BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for IMCIVREE® (setmelanotide) to include children as young as 2 years old. IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long-term in patients 2 years of ag ...

BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of results from its Phase 3 VENTURE trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in children between the ages of 2 and younger than 5 years old with Bardet Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), proprotein conv ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38223 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 46-2159271 (State ...

BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at two upcoming investor conferences: Guggenheim Securities Healthcare Innovation Conference on Monday, November 11 at 11:30 a.m. ET Stifel 2024 Healthcare Confere ...

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants David Connolly - Head of Investor Relations and Corporate Communications David Meeker - Chairman, President and Chief Executive Officer Jennifer Lee - Executive Vice President and Head of North America Yann Mazabraud - Executive Vice President and Head of International Hunter Smith - Chief Financial Officer Conference Call Participants Philip Nadeau - TD Cowen Corinne Johnson - Goldma ...